GW Pharma Epilepsy Drug Epidiolex Clinical Trial Shows Substantial Reduction in Seizures
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared...